Dyadic International (NASDAQ:DYAI)‘s stock had its “buy” rating restated by investment analysts at Noble Financial in a report released on Monday, TipRanks reports. They currently have a $11.00 price target on the biotechnology company’s stock. Noble Financial’s price objective would suggest a potential upside of 24.72% from the stock’s previous close.
Separately, ValuEngine upgraded Dyadic International from a “sell” rating to a “hold” rating in a report on Wednesday, March 4th.
DYAI opened at $8.82 on Monday. Dyadic International has a one year low of $2.51 and a one year high of $10.98. The stock’s fifty day moving average is $7.02 and its 200-day moving average is $5.82. The company has a market capitalization of $270.85 million, a PE ratio of -28.45 and a beta of 0.45.
Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.06). The firm had revenue of $0.32 million during the quarter, compared to the consensus estimate of $2.07 million. Dyadic International had a negative return on equity of 22.87% and a negative net margin of 523.65%. Research analysts expect that Dyadic International will post -0.23 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in shares of Dyadic International by 65.2% during the first quarter. Bank of New York Mellon Corp now owns 33,881 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 13,368 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Dyadic International by 4.4% during the first quarter. BlackRock Inc. now owns 60,126 shares of the biotechnology company’s stock valued at $313,000 after buying an additional 2,553 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Dyadic International by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 175,483 shares of the biotechnology company’s stock valued at $909,000 after buying an additional 2,723 shares in the last quarter. Credit Suisse AG purchased a new position in shares of Dyadic International during the fourth quarter valued at $327,000. Finally, Advisor Group Inc. grew its holdings in shares of Dyadic International by 8.5% during the fourth quarter. Advisor Group Inc. now owns 39,058 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 3,050 shares in the last quarter. Institutional investors and hedge funds own 12.90% of the company’s stock.
About Dyadic International
Dyadic International, Inc, a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
Featured Story: What are the advantages of the Stochastic Momentum Index?
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.